Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Medtronic (MDT – Research Report). The associated price target remains the same with $95.00. Josh Jennings has given his Buy ...

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report).

RBC Capital raised the firm’s price target on Medtronic to $98 from $92 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q3 results. The firm’s ...

Barclays raised their price target on Medtronic from $104.00 to $105.00 ... Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac ...

Medtronic plc MDT is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company’s adjusted earnings of $1.23 exceeded the ...

(Courtesy of Medtronic) At the time, pacemakers were “crude devices,” with wires coming out of the person’s body and “they were susceptible like anything that uses wall power,” said ...

NeurAxis (NASDAQ:NRXS – Get Free Report) and Medtronic (NYSE:MDT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength ...